External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment

Purpose: The aim of our study was the external validation of an extended variant of the four-tiered diagnosis-specific graded prognostic assessment (DS-GPA) that includes more information about extracranial disease burden and blood test results, and predicts survival of patients with brain metastase...

Full description

Bibliographic Details
Published in:Oncology Research and Treatment
Main Authors: Nieder, Carsten, Hess, Sebastian, Lewitzki, Victor
Format: Article in Journal/Newspaper
Language:English
Published: S. Karger AG 2020
Subjects:
Online Access:http://dx.doi.org/10.1159/000506954
https://www.karger.com/Article/Pdf/506954
id crskarger:10.1159/000506954
record_format openpolar
spelling crskarger:10.1159/000506954 2024-06-09T07:48:26+00:00 External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment Nieder, Carsten Hess, Sebastian Lewitzki, Victor 2020 http://dx.doi.org/10.1159/000506954 https://www.karger.com/Article/Pdf/506954 en eng S. Karger AG https://www.karger.com/Services/SiteLicenses https://www.karger.com/Services/SiteLicenses Oncology Research and Treatment volume 43, issue 5, page 221-227 ISSN 2296-5270 2296-5262 journal-article 2020 crskarger https://doi.org/10.1159/000506954 2024-05-15T13:31:32Z Purpose: The aim of our study was the external validation of an extended variant of the four-tiered diagnosis-specific graded prognostic assessment (DS-GPA) that includes more information about extracranial disease burden and blood test results, and predicts survival of patients with brain metastases. The extracranial DS-GPA (EC-GPA) includes serum albumin, lactate dehydrogenase, and number of extracranial organs involved. Originally, the score was developed in Germany. Patients and Methods: A retrospective analysis of 236 patients with brain metastases treated with primary whole-brain radiotherapy in North-Norway was performed (independent external validation cohort). Results: The four-tiered EC-GPA score showed good discrimination between all prognostic groups (log-rank test p < 0.05 for all pairwise comparisons). One-year survival was 0, 11, 30, and 100%, respectively. Median survival was 0.7 months (95% CI, 0.5–0.9) in the worst prognostic group, with a hazard ratio for death of 44.31 (95% CI, 5.78–339.50) compared to the best group. In the German database, the corresponding HR was 31.64 (median survival 0.4 months). The remaining hazard ratios in this validation study were 7.13 and 12.10, compared with 4.84 and 9.26 in the score development study. Conclusions: This study provides an independent validation of the EC-GPA, which was the best prognostic model for defining patients who did not benefit from radiation therapy of brain metastases in terms of overall survival in the original German study. The proposed modification of the established DS-GPA should undergo further validation in multi-institutional databases. Article in Journal/Newspaper North Norway Karger Norway Oncology Research and Treatment 43 5 221 227
institution Open Polar
collection Karger
op_collection_id crskarger
language English
description Purpose: The aim of our study was the external validation of an extended variant of the four-tiered diagnosis-specific graded prognostic assessment (DS-GPA) that includes more information about extracranial disease burden and blood test results, and predicts survival of patients with brain metastases. The extracranial DS-GPA (EC-GPA) includes serum albumin, lactate dehydrogenase, and number of extracranial organs involved. Originally, the score was developed in Germany. Patients and Methods: A retrospective analysis of 236 patients with brain metastases treated with primary whole-brain radiotherapy in North-Norway was performed (independent external validation cohort). Results: The four-tiered EC-GPA score showed good discrimination between all prognostic groups (log-rank test p < 0.05 for all pairwise comparisons). One-year survival was 0, 11, 30, and 100%, respectively. Median survival was 0.7 months (95% CI, 0.5–0.9) in the worst prognostic group, with a hazard ratio for death of 44.31 (95% CI, 5.78–339.50) compared to the best group. In the German database, the corresponding HR was 31.64 (median survival 0.4 months). The remaining hazard ratios in this validation study were 7.13 and 12.10, compared with 4.84 and 9.26 in the score development study. Conclusions: This study provides an independent validation of the EC-GPA, which was the best prognostic model for defining patients who did not benefit from radiation therapy of brain metastases in terms of overall survival in the original German study. The proposed modification of the established DS-GPA should undergo further validation in multi-institutional databases.
format Article in Journal/Newspaper
author Nieder, Carsten
Hess, Sebastian
Lewitzki, Victor
spellingShingle Nieder, Carsten
Hess, Sebastian
Lewitzki, Victor
External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment
author_facet Nieder, Carsten
Hess, Sebastian
Lewitzki, Victor
author_sort Nieder, Carsten
title External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment
title_short External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment
title_full External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment
title_fullStr External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment
title_full_unstemmed External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment
title_sort external validation of a prognostic score for patients with brain metastases: extended diagnosis-specific graded prognostic assessment
publisher S. Karger AG
publishDate 2020
url http://dx.doi.org/10.1159/000506954
https://www.karger.com/Article/Pdf/506954
geographic Norway
geographic_facet Norway
genre North Norway
genre_facet North Norway
op_source Oncology Research and Treatment
volume 43, issue 5, page 221-227
ISSN 2296-5270 2296-5262
op_rights https://www.karger.com/Services/SiteLicenses
https://www.karger.com/Services/SiteLicenses
op_doi https://doi.org/10.1159/000506954
container_title Oncology Research and Treatment
container_volume 43
container_issue 5
container_start_page 221
op_container_end_page 227
_version_ 1801380145222647808